-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Novel Immunotherapies in the Treatment of AML, Is There a Hope?

Program: Education Program
Session: What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?
Hematology Disease Topics & Pathways:
Research, Biological therapies, clinical trials, Acute Myeloid Malignancies, AML, Antibody Therapy, adult, Translational Research, Bispecific Antibody Therapy, Clinical Research, Combination therapy, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Checkpoint Inhibitor, pediatric, Diseases, immune mechanism, Gene Therapy, Therapies, immunology, Immunotherapy, Adverse Events, Myeloid Malignancies, Biological Processes, Monoclonal Antibody Therapy, Technology and Procedures, Natural Killer (NK) Cell Therapies, Study Population, Human, Minimal Residual Disease
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Marion Subklewe, MD

Department of Medicine III (Hem/Onc), Ludwig-Maximilians-University Hospital Munich, Munich, Germany

Disclosures: Subklewe: Molecular Partners: Consultancy, Honoraria, Research Funding; Miltenyi Biotec: Consultancy, Honoraria, Research Funding; Seagen: Research Funding; Ichnos Sciences: Consultancy, Honoraria; AvenCell: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Research Funding; Incyte Biosciences: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Other: Travel Support, Speakers Bureau; Novartis: Consultancy, Honoraria, Research Funding, Speakers Bureau; Roche: Consultancy, Honoraria, Other: Travel Support, Research Funding, Speakers Bureau; AstraZeneca: Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Gilead/Kite: Consultancy, Honoraria, Other: Travel Support, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria, Research Funding; GSK: Speakers Bureau; LAWG: Speakers Bureau; Springer Healthcare: Speakers Bureau; AbbVie: Consultancy, Honoraria; Autolus: Consultancy, Honoraria; advesya (CanCell Therapeutics): Consultancy, Honoraria; Genmab US: Consultancy, Honoraria; Interius BioTherapeutics: Consultancy, Honoraria; Nektar Therapeutics: Consultancy, Honoraria; Orbital Therapeutics: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Scare: Consultancy, Honoraria.